CymaBay Therapeutics Inc
Save
–
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes.
Similar securities
Based on sector and market capitalization
Report issue